NetworkNewsBreaks – Second Sight (NASDAQ: EYES): UK Government Greenlights Funding for Argus II “Bionic Eye” Implants
Second Sight Medical Products (NASDAQ: EYES) has made a groundbreaking achievement after advisors issued a positive recommendation to the UK Government’s healthcare funding authority for specialized services in England. For the first time in the UK, the publicly funded NHS system will fund blind patients with Retinitis Pigmentosa (RP) to receive treatment with Second Sight’s innovative Argus® II Retinal Prosthesis System (Argus II) “bionic eye.” A selective group of severely blind patients with RP will have access to Argus II, the world’s first and only routinely used treatment for severe blindness. The hospitals and Second Sight will provide follow up,…